TY - JOUR T1 - Evaluation of the Panbio™ COVID-19 Ag Rapid Test at an Emergency Room in a Hospital in São Paulo, Brazil JF - medRxiv DO - 10.1101/2021.03.15.21253313 SP - 2021.03.15.21253313 AU - Klinger Soares Faíco-Filho AU - Francisco Estivallet Finamor Júnior AU - Luiz Vinícius Leão Moreira AU - Paulo Ricardo Gessolo Lins AU - Alberto Fernando Oliveira Justo AU - Nancy Bellei Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/24/2021.03.15.21253313.abstract N2 - Introduction The performance characteristics of the Panbio™ COVID-19 Ag test were evaluated against RT-PCR – considered the gold-standard for the detection of SARS-CoV-2 – at an emergency room in São Paulo, Brazil. The study aimed to determine the sensitivity, specificity, positive percent agreement (PPA), and negative percent agreement (NPA) as compared to RT-PCR.Methods Specimens from 127 suspected patients were tested by both the Panbio™ COVID-19 Ag test and by RT-PCR.Results Evaluation of the agreement between the Panbio™ COVID-19 Ag test and RT-PCR indicated an overall sensitivity of 84% (95%CI, 75-93.8%) and an overall specificity of 98% (95%CI, 96-98.8%). The Panbio™ COVID-19 Ag test showed 97% sensitivity and 99% NPA for subjects with Ct values ≤ 25 (N=37).Conclusion The Panbio™ COVID-19 Ag test is suitable for use as a diagnostic test for the rapid screening of patients presenting COVID-19 symptoms, or those suspected with being infected, prior to being admitted to hospital.Competing Interest StatementNancy Bellei received fees for lectures and the advisory board for AbbottFunding StatementNo funding for this study. Panbio antigen test was provided by Abbott. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by UNIFESP ethical committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data of the manuscript on virologia.unifesp{at}gmail.com ER -